Patients

Our commitment to patients through biosimilars

At Fresenius Kabi, we are proud of our long-held tradition of putting patients first. We do this through our high-quality and affordable products, allied to the renowned support services we have created for both patients and healthcare professionals.

We are strengthening this tradition through the ongoing growth of our biosimilars operation. Biosimilars help more and more patients to have access to the treatment they need to combat critical and chronic illnesses.

By working closely with healthcare professionals and patients – and by using genuine insights into what these groups really need and want – we have been able to develop value-added services to improve care for patients on our biosimilars products.

This is especially important, as the transition to a biosimilar medicine should be as simple, reassuring and rewarding as possible. At the same time, we have to recognise that different people with different conditions require different levels of information and support.

Supporting patients beyond their disease

Seamlessly connecting biosimilar products with our innovative patient support program helps patients live beyond their disease. It also allows us to leverage the value that these support programs provide.

Our KabiCare patient support program not only supports patients, it also aims to improve patient-physician communication. This is especially helpful when treating more complex conditions.

We passionately believe in Caring for Life

Our passion about “caring for life” is behind everything we do for patients and healthcare professionals. Every day, our 40,000 employees embody this philosophy. It is our commitment to doing everything we can, as an organization, to help improve patients’ quality of life.

Caring for life is about putting essential medicines and technologies into the hands of people who help patients – together with our world-leading support programme, KabiCare. We firmly believe that this is one of the best ways of finding the answers to the challenges these patients face from living with their illnesses.
 

Find out how we are supporting biosimilars patients.